Amakuru

Ku ya 12 Werurwe^th 2022, iNMPA (SFDA) yasohoye itangazo ryemeza impinduka zo gusaba kwipimisha ibicuruzwa bya COVID-19 na Nanjing Vazyme BiotechCo., Ltd., Beijing Jinwofu Ikoranabuhanga rya BioengineeringCo., Ltd., Shenzhen Huada Yinyuan Pharmaceutical Technology Co., Ltd., Guangzhou Wondfo Biotech Co., Ltd. naBeijing Savant Biotechnology Co, ltd(Huaketai).Ibicuruzwa bitanu bya COVID-19 byo kwipimisha antigen byatangijwe.

Ku ya 11 Werurwe 2022, NHC yari yatangaje ko, mu rwego rwo kurushaho kunoza ingamba zo gupima Novel Coronavirus no guharanira ibikenewe mu gukumira no kugenzura COVID-19, Itsinda ryuzuye ry’uburyo bukomatanyije bwo gukumira no kugenzura Inama y’igihugu yiyemeje kongeraho kwipimisha antigen mugupima aside nucleic hanyuma ikora "Porotokole yo gusaba kuri Novel Coronavirus Antigen Detection (Ikigeragezo)"
Porotokole yerekana abaturage bakoreshwa mugupima antigen:
Ubwa mbere, abasuye ibigo byubuvuzi byambere kandi bafite ibimenyetso nkinzira zubuhumekero numuriro mugihe cyiminsi 5 uhereye ibimenyetso bitangiye;
Icya kabiri, abakozi bashinzwe gukurikirana akato, harimo kwitegereza akato mu rugo, guhuza hafi no guhuza hafi, kureba akato kinjira, aho bagenewe n'abakozi bashinzwe kugenzura;
Icya gatatu ni abaturage batuye bakeneye kwimenyekanisha kwa antigen.

Inama: Kumenya antigen ninyongera yingirakamaro yo kumenya aside nucleic, ariko ibisubizo byo kwimenyekanisha kwa antigen ntibishobora gukoreshwa nkibanze mu gusuzuma indwara.